Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.

Journal of pediatric hematology/oncology - 1 Nov 2008

Davidsen Marie Louise, Dalhoff Kim, Schmiegelow Kjeld

Abstract excerpt

Pharmacogenetics covers the genetic variation affecting pharmacokinetics and pharmacodynamics, and their influence on drug-response phenotypes. The genetic variation includes an estimated 15 million single nucleotide polymorphisms (SNPs) and is a key determinator for the interindividual differences in treatment resistance and toxic side effects. As most childhood acute lymphoblastic leukemia treatment protocols...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Neoplasm Proteins

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Treatment Outcome

Source

Identifiers

PMID: 18989161
DOI: 10.1097/MPH.0b013e3181868570

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.PMID 18989161Read ↗

Thiopurine S-methyltransferase pharmacogenetics in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Pharmacogenetics of Childhood Acute Lymphoblastic Leukemia.Semantic proximity Read ↗

Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.Semantic proximity Read ↗

Pharmacogenetics of Childhood Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.Semantic proximity Read ↗

Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease and autoimmune disorders: influence on treatment responseSemantic proximity Read ↗

Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy.Semantic proximity Read ↗

The Promise of Pharmacogenomics in Reducing Toxicity during Acute Lymphoblastic Leukemia Maintenance TreatmentSemantic proximity Read ↗

Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemiaSemantic proximity Read ↗

Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug TransportersSemantic proximity Read ↗

Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.